- Institutions (865)
- Other institutions (54)
Adlbrecht, C. and Breyer, E. and Gartlehner, G. and Guba, B. (2008): Selective Cell Apheresis in Inflammatory Bowel Disease. Decision Support Document 11.
Arrich, J. and Piribauer, F. and Mad, P. and Schmid, D. (2005): Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: Systematic review and meta-analysis. CMAJ: Canadian Medical Association Journal 172 (8): 1039-1043.
Breuer, J. and Joppi, R. and Poggiani, C. and Dabrowska, M. and Zawodnik, A. and Nachtnebel, A. (2014): Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 45.
Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.
Breyer, E. (2008): [Templates for reimbursement applications]. Masters.
Dental and Pharmaceutical Benefits Agency (TLV), EUnetHTA and Main Association of Austrian Social Security Institutions (HVB), EUnetHTA and Agency for Quality and Accreditation in Health Care and Social Welfare (AAZ), EUnetHTA (2018): Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report. DSD: Horizon Scanning in Oncology 77.
Erdös, J. and Ibargoyen Roteta, N. and Gutiérrez Ibarluzea, I. (2017): Repetitive transcranial magnetic stimulation for treatment-resistant major depression. Decision Support Document 107.
Erdos, J. and Mayer, J. (2015): Sphenopalatine Ganglion (SPG) stimulation of patients with therapy-resistant cluster headache. Decision Support Document 86.
Ettinger, S. and Stanak, M. and Huić, M. and Hacek, R.T. and Ercevic, D. and Grenkovic, R. and Wild, C. (2016): Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk.. Decision Support Document 103.
Finnish Medicines Agency (FIMEA), EUnetHTA and Norwegian Medicines Agency (NoMA), EUnetHTA (2017): Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia. EUnetHTA report. DSD: Horizon Scanning in Oncology 74.
Fischer, S. and Zechmeister-Koss, I. (2015): Intrastromal corneal implants for ectatic corneal disorders. Decision Support Document 85.
Fried, A. and Wild, C. (2013): Hybrid operating room. Rapid Assessment 006.
Galician Agency for Health Technology Assessment (avalia-t), EUnetHTA and Regione Emilia Romagna (RER), EUnetHTA (2018): Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA-Report. HTA-Projektbericht 103.
Haute Autorité de Santé (HAS), EUnetHTA and Autoridade Nacional do Medicamento e Productos de Saude (INFARMED), EUnetHTA (2017): Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. EUnetHTA report. DSD: Horizon Scanning in Oncology 73.
Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.
Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.
Joppi, R and Nachtnebel, A. (2012): Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma. DSD: Horizon Scanning in Oncology 34.
Joppi, R. and Nachtnebel, A. (2012): Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma . DSD: Horizon Scanning in Oncology 30.
Kisser, A. and Kirisits, A. (2015): Endovascular embolization of unruptured intracranial aneurysms with flow diverters. Decision Support Document 83.
Mad, P. and Domanovits, H. and Fazelnia, C. and Stiassny, K. (2007): Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. QJM: An International Journal of Medicine 100 (4): 203-210.
McGahan, L. (2016): Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. DSD: Horizon Scanning in Oncology 61.
Nachtnebel, A. and Maran , P.R. and Alberti, C. and Garbaty , T. and Czeczot , J. (2012): Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion. DSD: Horizon Scanning in Oncology 28.
Nachtnebel, A. and Polkowska, M. and Czeczot , J. and Joppi, R. and Poggiani, C. (2013): Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer . DSD: Horizon Scanning in Oncology 36.
Nachtnebel, A. and Reinsperger, I. (2012): Percutaneous repair of mitral regurgitation with the MitraClip® . Decision Support Document 41 / Update 2012.
Nachtnebel, A. and Ujeyl, M. (2015): Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. DSD: Horizon Scanning in Oncology 53.
Naimer, Ch. and Piso, B. (2015): Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review. Decision Support Document 92.
Piso, B. and Tüchler, H. (2016): Outpatient cardiac rehabilitation part VI: prospective multi-centre cohort study (comparing patients with and without phase III). HTA-Projektbericht 90.
Poggiani, C. and Hintringer, K. (2012): Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC) . DSD: Horizon Scanning in Oncology 21.
Poggiani, C. and Nachtnebel, A. (2012): Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma. DSD: Horizon Scanning in Oncology 33.
Reinsperger, I. and Piso, B. (2015): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (2nd Update 2015). Decision Support Document 44/ 2. Update 2015.
Reinsperger, I. and Piso, B. (2015): Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB) (1st Update 2015). Decision Support Document 68/ 1. Update 2015.
Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.
Rothschedl, E. and Nachtnebel, A. (2015): Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document 84.
Salamon, Maria (2016): Screening, diagnostics and indication for occupational therapy in children and adolescents with Developmental Coordination Disorders. Decision Support Document 96.
Sassi, F. and McDaid, D. (1998): Transnational analysis of the socio-economic impact of Alzheimer's disease (AD) in the European Union. Report to DG V of the European Commission.
Semlitsch , T. and Jeitler, K. (2013): Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) . DSD: Horizon Scanning in Oncology 35.
Semlitsch, T. and Horvath, K. (2016): Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB). 2nd Update 2016 . Decision Support Document 24/ 2. Update 2016.
Semlitsch, T. and Posch, N. (2017): Leadless pacemakers for right ventricle pacing. Update 2017. Decision Support Document 97/ 1. Update 2017.
Semlitsch, T. and Posch, N. (2017): Percutaneous disc volume reduction with focus on chemonucleolysis. Update 2017. Decision Support Document 21/ 1. Update 2017.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2014): Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas. DSD: Horizon Scanning in Oncology 43.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2013): Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma. DSD: Horizon Scanning in Oncology 42.
Ujeyl, M. and Nachtnebel, A. (2015): Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. DSD: Horizon Scanning in Oncology 50.
Wild, C. (1996): [Medical technology assessment: The social implications of the increasing spread of technology in health care]. In: Tichy, G. Technikfolgenabschätzung in Österreich: Wien: Verlag der Österreichischen Akademie der Wissenschaften.
Wild, C. and Gregor-Patera, N. (2015): HTA-Strategy for Lithuania. Decision Support Document 90a.
Wild, C. and Gregor-Patera, N. and Stricka, M. and Karnickas, L. (2015): Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices. Decision Support Document 90.
Wild, C. and Peissl, W. (1996): [Patient cards: An assessment of a new information technology in health care]. In: Tichy, G. Technikfolgenabschätzung in Österreich – Entscheidungshilfe in einer komplexen Welt, Beispiele aus der Praxis: Wien: Verlag der Österreichischen Akademie der Wissenschaften.
Winkler, R. (2015): Transcatheter mitral valve-in-valve implantation. Decision Support Document 82.
Winkler, R. (2015): Injectable bulking agents for faecal incontinence. Decision Support Document 87.
Zechmeister, I. and Österle, A. (2006): Distributional impacts of mental health care financing arrangements: A comparison of the UK, Germany and Austria. Journal of Mental Health Policy and Economics 9 (1): 34-44.
Zechmeister, I. and Stollenwerk, B. and Ara, R. and Ward, S. (2008): Statins for the Secondary Prevention of Cardiovascular Diseases: An Analysis of Expected Population Health Gains and Cost-Utility in Austria (Part II of the project 'Statins: A comparison between predicted and actual effects on population health in Austria') . HTA-Projektbericht 018.
Zechmeister, I. and Stollenwerk, B. and Langley, T. (2008): Have Statins Met Our Expectations? A Comparison of Expected Health Gains from Statins with Epidemiological Trends in Austria (Part III of the Project 'Statins: A Comparison Between Predicted and Actual Effects on Population Health in Austria'). HTA-Projektbericht 019.
Zechmeister-Koss, I. (2013): Zostavax® for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA Core Model for Rapid Relative Effectiveness Assessment. Pilot-ID: WP-SA-1. Decision Support Document 73.
Zechmeister-Koss, I. and Rothschedl, E. (2015): Fully bioresorbable scaffolds for coronary artery disease. Decision Support Document 81.
Zorginstituut Nederland (ZIN), EUnetHTA and Belgian Health Care Knowledge Centre (KCE), EUnetHTA (2018): MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EUnetHTA report . HTA-Projektbericht 102.